Archive · 3 Aug 2025
Russia to Start Cancer Vaccine Trials in Months, Targeting Melanoma
Russian scientists are developing a new cancer vaccine that is made just for each person.
It uses a person's own tumor information to teach the body's defenses to find and destroy cancer cells.
The vaccine is being tested on melanoma patients first, with plans to expand to other types of cancer.
The vaccine has shown good results in early tests and will be free for Russians.
The process takes about a week to make each vaccine, and other countries are interested in working with Russia on this project.
Russia is preparing to begin experimental treatment using a personalized cancer vaccine.
The mRNA-based vaccine is tailored to each patient using their unique tumor data.
Development of the vaccine began in mid-2022, using mRNA and AI.
The vaccine has shown promising results in animal studies and limited human trials.
The vaccine will be distributed free of cost to Russian citizens.
- Who
- The Gamaleya Research Institute of Epidemiology and Microbiology is developing the vaccine for Russian citizens.
- What
- Development of a personalized cancer vaccine using mRNA technology.
- When
- First patients may receive the vaccine in the coming months; development began in mid-2022.
- Where
- Trials will be conducted at research institutes in Moscow, Russia.
- Why
- To treat cancer patients by training the immune system to target and destroy malignant cells.
- Vaccine Type
- mRNA-based
- Target Cancers
- Melanoma; other cancers like pancreatic and lung
- Production Time
- About a week per vaccine
- Estimated Cost per Dose
- 300,000 rubles (USD 2,869)
- Status
- Experimental treatment phase
- Distribution
- Free to Russian citizens